drugset
drugset / Trial / NCT01090622

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

NCT01090622 ↗

Phase 1/2 Completed 4 enrolled Xenon Pharmaceuticals Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).

Timeline

Start
2010-04
Primary completion
2010-08
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject XPF-001 Unknown — Oral

Indications

primary erythermalgia